tradingkey.logo

Black Diamond Therapeutics Inc <BDTX.OQ> expected to post a loss of 29 cents a share - Earnings Preview

ReutersMar 7, 2025 12:32 PM
  • Black Diamond Therapeutics Inc BDTX.OQ BDTX.O is expected to show no change in quarterly revenue when it reports results on May 7 (estimated) for the period ending March 31 2025

  • ​LSEG's mean analyst estimate for Black Diamond Therapeutics Inc is for a loss of 29 cents per share.

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

  • The mean earnings estimate of analysts was unchanged in the last three months. ​

  • Wall Street's median 12-month price target for Black Diamond Therapeutics Inc is $15.00​, above​ its last closing price of $1.90. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING

STARMINESMARTESTIMATE®

LSEG IBES ESTIMATE

ACTUAL

BEAT, MET, MISSED

SURPRISE %

Dec. 31 2024

-0.31

-0.28

Beat

11

Sep. 30 2024

-0.38

-0.37

-0.28

Beat

25.1

Jun. 30 2024

-0.38

-0.39

-0.36

Beat

7​

Mar. 31 2024

-0.42

-0.43

-0.35

Beat

19.5

​​Dec. 31 2023

-0.45

-0.47

-0.34

Beat

27

Sep. 30 2023

-0.44

-0.49

-0.45

Beat

7.5​

Jun. 30 2023

-0.54

-0.54

-0.52

Beat

3

Mar. 31 2023

-0.61

-0.61

-0.57

Beat

6.2

This summary was machine generated March 7 at 12:32 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

Tradingkey
KeyAI